Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jan 26, 2021 9:45 AM - Jan 28, 2021 5:00 PM

(US Eastern Standard Time)

Pharmacovigilance and Risk Management Strategies Conference

Session 7: Artificial Intelligence and Natural Language Processing: Offering True Benefits to PV Organizations Today

Session Chair(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Mariette Boerstoel-Streefland, MD, MBA, MS

Senior Vice President, Worldwide Safety Officer

Bristol-Myers Squibb Company, United States

Lisa Melanie Harinstein, PharmD

Lisa Melanie Harinstein, PharmD

Team Leader, Division of Pharmacovigilance, FDA

FDA, United States

Annette S. Williams, MBA, RPh

Annette S. Williams, MBA, RPh

Vice President, Pharmacovigilance

IQVIA, United States

Life science companies are actively pursuing automated solutions to address the challenge of managing increasing volumes of safety-related data from a myriad of sources, as well as to help identify, extract and interpret data for improved pharmacovigilance (PV). Assessing technology tools – such as robotic process automation (RPA), and natural language processing (NLP) has become more commonplace. This session will focus on specific use cases across the pharmacovigilance continuum. It will showcase how AI/NLP is being applied to increase robustness and efficiency for AE case intake from various territories across the globe. We will explore how NLP is now being employed to identify patients at risk in clinical trials as well as develop safety-related intelligence landscapes from scientific literature, internal preclinical and clinical safety reports that can be used to contextualize potential safety signals, as well as how regulatory agencies are utilizing the technology for pharmacovigilance.

Learning Objective :
  • Define AI, RPA, and NLP and its application
  • Outline how pharma organizations are using NLP for safety applications; including limitations and validation
  • What is the current situation; where are various stakeholders in their use of AI
  • Understand effective utilization of AI and NLP for intake of AE information from various territories worldwide
  • List how the FDA is applying AI to pharmacovigilance strategies.

Speaker(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Global Intake Using NLP, Translation, AI in an Ever-changing PV Organization part 1

Mariette Boerstoel-Streefland, MD, MBA, MS

Bristol-Myers Squibb Company, United States

Senior Vice President, Worldwide Safety Officer

Francois  Audibert, MSc

Global Intake Using NLP, Translation, AI in an Ever-Changing PV Organization part 2

Francois Audibert, MSc

Vitrana, United States

Vice President – U.S. Operations

Jane  Reed, PhD

New Uses of Natural Language Processing (NLP) in Product Safety

Jane Reed, PhD

Linguamatics, United Kingdom

Director, Life Science

Oanh  Dang, PharmD

Leveraging Applied AI Within Pharmacovigilance

Oanh Dang, PharmD

FDA, United States

Pharmacotherapy Specialist, Regulatory Science Staff, OSE, CDER

Allan  Fong, MS

Patient Safety Monitoring using NLP and Machine Learning: A Healthcare Perspective

Allan Fong, MS

Medstar Health National Center For Human Factors In Healthcare, United States

Research Scientist and Data Scientist

Aaron Zachary Hettinger, MD, MS

Speaker

Aaron Zachary Hettinger, MD, MS

Medstar Health National Center For Human Factors In Healthcare, United States

Director of Cognitive Informatics

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.